PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells

@inproceedings{Ito2016PARPII,
  title={PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells},
  author={Shuhei Ito and Conleth Gerard Murphy and Ekaterina S. Doubrovina and Maria Jasin and Mary Ellen Moynahan},
  booktitle={PloS one},
  year={2016}
}
Poly(ADP-ribose) polymerases (PARPs) are the first proteins involved in cellular DNA repair pathways to be targeted by specific inhibitors for clinical benefit. Tumors harboring genetic defects in homologous recombination (HR), a DNA double-strand break (DSB) repair pathway, are hypersensitive to PARP inhibitors (PARPi). Early phase clinical trials with PARPi have been promising in patients with advanced BRCA1 or BRCA2-associated breast, ovary and prostate cancer and have led to limited… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS